|
1
|
Siegel RL, Wagle NS, Cercek A, Smith RA
and Jemal A: Colorectal cancer statistics, 2023. CA Cancer J Clin.
73:233–254. 2023.PubMed/NCBI
|
|
2
|
Li X, Jonnagaddala J, Yang S, Zhang H and
Xu XS: A retrospective analysis using deep-learning models for
prediction of survival outcome and benefit of adjuvant chemotherapy
in stage II/III colorectal cancer. J Cancer Res Clin Oncol.
148:1955–1963. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nakamura Y, Yamaura T, Kinjo Y, Harada K,
Kawase M, Kawabata Y, Kanto S, Ogo Y and Kuroda N: Level of
inferior mesenteric artery ligation in sigmoid colon and rectal
cancer surgery: analysis of apical lymph node metastasis and
recurrence. Dig Surg. 40:167–177. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Geng S, Yu X and Yu S: Efficacy and safety
of natural killer cells injection combined with XELOX chemotherapy
in postoperative patients with stage III colorectal cancer in
China: A prospective randomised controlled clinical trial study
protocol. BMJ Open. 14:e0803772024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kobayashi K, Ono Y, Kitano Y, Oba A, Sato
T, Ito H, Mise Y, Shinozaki E, Inoue Y, Yamaguchi K, et al:
Prognostic impact of tumor markers (CEA and CA19-9) on patients
with resectable colorectal liver metastases stratified by tumor
number and size: Potentially valuable biologic markers for
preoperative treatment. Ann Surg Oncol. 30:7338–7347. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grange R, Rousset P, Williet N, Guesnon M,
Milot L, Passot G, Phelip JM, Le Roy B, Glehen O and Kepenekian V:
Metastatic colorectal cancer treated with combined liver resection,
cytoreductive surgery, and hyperthermic intraperitoneal
chemotherapy (HIPEC): Predictive factors for early recurrence. Ann
Surg Oncol. 31:2378–2390. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Elfiky AM, Eid MM, El-Manawaty M, Elshahid
ZA, Youssef EM and Mahmoud K: Production of novel theranostic
nano-vector based on superparamagnetic iron oxide
nanoparticles/miR-497 targeting colorectal cancer. Sci Rep.
15:42472025. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han S, Chen Y, Wang Y and Xu H:
Application of problem-oriented nursing model combined with early
enteral nutrition support in the perioperative period of stage
II/III gastric cancer patients. Nutr Cancer. 77:1028–1034. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao Q, Li Y and Wang T: Development and
validation of prediction model for early warning of ovarian
metastasis risk of endometrial carcinoma. Medicine (Baltimore).
102:e354392023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu J, Du L, Lei X and Zhang Z: Prognostic
value of esophageal cancer immune prognostic index in advanced
esophageal squamous cell carcinoma patients with anti-programmed
cell death-1 therapy. Cancer Med. 12:11334–11343. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peng Q, Shen Y, Zhao P, Cheng M, Wu Y and
Zhu Y: Biomarker implication of kallikrein-related peptidases as
prognostic tissue substrates of poor survival in colorectal cancer.
Cancer Cell Int. 20:2602020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abuduhadeer X, Xu X, Aihesan K, Yilihamu
M, Zhao Y and Zhang W: Clinical significance of kallikrein 5 as a
novel prognostic biomarker in gastric adenocarcinoma. J Clin Lab
Anal. 35:e239582021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang X, Zheng S, Li S, Huang Y, Zhang W,
Liu F and Cao Q: Machine learning-based pathomics model predicts
angiopoietin-2 expression and prognosis in hepatocellular
carcinoma. Am J Pathol. 195:561–574. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng J, Du PZ, Yang C, Tao YY, Li L, Li
ZM and Yang L: DCE-MRI-based radiomics in predicting angiopoietin-2
expression in hepatocellular carcinoma. Abdom Radiol (NY).
48:3343–3352. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Saeed A, Park R, Pathak H, Al-Bzour AN,
Dai J, Phadnis M, Al-Rajabi R, Kasi A, Baranda J, Sun W, et al:
Clinical and biomarker results from a phase II trial of combined
cabozantinib and durvalumab in patients with
chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC
cohort. Nat Commun. 15:15332024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ishikawa S, Hirano Y, Deguchi K, Ishii T,
Ishiyama Y, Okazaki N, Fujii T, Kataoka A, Sasaki M, Shimamura S
and Yonezawa H: Risk factors for lymph node metastasis and
recurrence in T1 colorectal cancer: analysis of 801 patients in a
single institute. Am Surg. 89:5312–5317. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ishimaru K, Kawai K, Nozawa H, Sasaki K,
Murono K, Emoto S, Ishii H, Anzai H, Sonoda H, Yamauchi S, et al:
Hazard function analysis of metastatic recurrence after colorectal
cancer surgery-A nationwide retrospective study. J Surg Oncol.
123:1015–1022. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Koedam TWA, Bootsma BT, Deijen CL, van de
Brug T, Kazemier G, Cuesta MA, Fürst A, Lacy AM, Haglind E, Tuynman
JB, et al: Oncological outcomes after anastomotic leakage after
surgery for colon or rectal cancer: Increased risk of local
recurrence. Ann Surg. 275:e420–e427. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Alkader MS, Al-Majthoub MZ, Al-Qerem WA,
Alkhader DM, Alhusban AM, Abdulkareem MA, Abweny B, Hamawi AT,
Muslem HF, Omeish RA, et al: Prognostic factors influencing
survival in stage II and stage III colorectal cancer patients.
Cureus. 15:e465752023.PubMed/NCBI
|
|
20
|
Dinart D, Bellera C and Rondeau V: Sample
size estimation for cancer randomized trials in the presence of
heterogeneous populations. Biometrics. 78:1662–1673. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Argilés G, Tabernero J, Labianca R,
Hochhauser D, Salazar R, Iveson T, Laurent-Puig P, Quirke P,
Yoshino T, Taieb J, et al: Localised colon cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 31:1291–1305. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Morris VK, Kennedy EB, Baxter NN, Benson
AB III, Cercek A, Cho M, Ciombor KK, Cremolini C, Davis A, Deming
DA, et al: Treatment of metastatic colorectal cancer: ASCO
guideline. J Clin Oncol. 41:678–700. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang Y, Yang Z, Lyu Z, Ouyang K, Wang J,
Wu D and Li Y: Pathological-features-modified TNM staging system
improves prognostic accuracy for rectal cancer. Dis Colon Rectum.
67:645–654. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shiina O, Kudo SE, Ichimasa K, Takashina
Y, Kouyama Y, Mochizuki K, Morita Y, Kuroki T, Kato S, Nakamura H,
et al: Differentiation grade as a risk factor for lymph node
metastasis in T1 colorectal cancer. DEN Open. 4:e3242023.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Joanito I, Wirapati P, Zhao N, Nawaz Z,
Yeo G, Lee F, Eng CLP, Macalinao DC, Kahraman M, Srinivasan H, et
al: Single-cell and bulk transcriptome sequencing identifies two
epithelial tumor cell states and refines the consensus molecular
classification of colorectal cancer. Nat Genet. 54:963–975. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tan Y, Liu R, Xue JW and Feng Z:
Construction and validation of artificial intelligence pathomics
models for predicting pathological staging in colorectal cancer:
Using multimodal data and clinical variables. Cancer Med.
13:e69472024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu C and Zhang F: LncRNA AC009022.1
enhances colorectal cancer cells proliferation, migration, and
invasion by promoting ACTR3B expression via suppressing miR-497-5p.
J Cell Biochem. 121:1934–1944. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou J and Yang D: Prognostic significance
of hemoglobin, albumin, lymphocyte and platelet (HALP) score in
hepatocellular carcinoma. J Hepatocell Carcinoma. 10:821–831. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang W, Zhang X, Zhao D, Hu M, Ge X and
Xia L: An individualized EMT-related gene signature to predict
recurrence-free survival in stage II/III colorectal cancer
patients. Dig Dis Sci. 67:5116–5126. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gattuso G, Longo F, Spoto G, Ricci D,
Lavoro A, Candido S, Di Cataldo A, Broggi G, Salvatorelli L, Magro
G, et al: Diagnostic and prognostic significance of a four-miRNA
signature in colorectal cancer. Int J Mol Sci. 26:12192025.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li J, Lei C, Chen B and Zhu Q: LncRNA
FGD5-AS1 facilitates the radioresistance of breast cancer cells by
enhancing MACC1 expression through competitively sponging
miR-497-5p. Front Oncol. 11:6718532021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kattan SW, Hobani YH, Abubakr Babteen N,
Alghamdi SA, Toraih EA, Ibrahiem AT, Fawzy MS and Faisal S:
Association of B-cell lymphoma 2/microRNA-497 gene expression ratio
score with metastasis in patients with colorectal cancer: A
propensity-matched cohort analysis. J Clin Lab Anal. 36:e242272022.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Song M and Liu J: Circ_0067717 promotes
colorectal cancer cell growth, invasion and glutamine metabolism by
serving as a miR-497-5p sponge to upregulate SLC7A5. Histol
Histopathol. 38:53–64. 2023.PubMed/NCBI
|
|
34
|
Bai J, Xu J, Zhao J and Zhang R: lncRNA
SNHG1 cooperated with miR-497/miR-195-5p to modify
epithelial-mesenchymal transition underlying colorectal cancer
exacerbation. J Cell Physiol. 235:1453–1468. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen K, Wang Z, Zong QB, Zhou MY and Chen
QF: miR-497-5p-RSPO2 axis inhibits cell growth and metastasis in
glioblastoma. J Cancer. 13:1241–1251. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao X, Dou LZ, Zhang YM, Liu Y, He S, Ke
Y, Liu XD, Liu YM, Wu HR, Li ZQ, et al: Risk factors for residual
cancer or lymph node metastasis after endoscopic noncurable
resection of early colorectal cancer. Zhonghua Zhong Liu Za Zhi.
45:335–339. 2023.(In Chinese). PubMed/NCBI
|
|
37
|
Wang L, Chen X, Zhang H, Hong L, Wang J,
Shao L, Chen G and Wu J: Comprehensive analysis of transient
receptor potential channels-related signature for prognosis, tumor
immune microenvironment, and treatment response of colorectal
cancer. Front Immunol. 13:10148342022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang Z, Liang Y, Zhong D, Dai Z, Shang J,
Lai C, Zou H, Yao Y, Feng T and Huang X: Prognostic value of
inflammation-immunity-nutrition score in patients with
hepatocellular carcinoma treated with anti-PD-1 therapy. J Clin Lab
Anal. 36:e243362022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lv Q, Rao SQ and Xiang Z: Preoperative
hemoglobin to albumin ratio as a prognostic predictor for patients
with colorectal cancer surgery. Updates Surg. 77:761–769. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Záhorec R, Marek V, Waczulikova I,
Veselovský T, Palaj J, Kečkéš Š and Durdík Š: Predictive model
using hemoglobin, albumin, fibrinogen, and neutrophil-to-lymphocyte
ratio to distinguish patients with colorectal cancer from those
with benign adenoma. Neoplasma. 68:1292–1300. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li K, Yan J, Zhang H, Lu C, Wang W, Guo M,
Zhang X and Zhang Z: Prognostic value of preoperative white blood
cell to hemoglobin ratio and fibrinogen to albumin ratio in
patients with colorectal cancer. Medicine (Baltimore).
103:e370312024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ambrosio MR, Spagnoli L, Perotti B,
Petrelli F, Caini S, Saieva C, Usai S, Bianchini M, Cavazzana A,
Arganini M and Amorosi A: Paving the path for immune enhancing
nutrition in colon cancer: Modulation of tumor microenvironment and
optimization of outcomes and costs. Cancers (Basel). 15:4372023.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fang Y, Lin L, Ruan H and Qin X: Natural
orifice specimen extraction surgery yields superior long-term
oncological outcomes compared to traditional laparoscopic surgery
in stage II–III rectal cancer. Am J Cancer Res. 15:3286–3298. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pei J, Gao Y and Wu A: An
inflammation-related subtype classification for analyzing tumor
microenvironment and clinical prognosis in colorectal cancer. Front
Immunol. 15:13697262024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chang JS, Kim N, Kim JY, Do SI, Cho Y, Kim
HS and Kim YB: Kallikrein 5 overexpression is associated with poor
prognosis in uterine cervical cancer. J Gynecol Oncol. 31:e782020.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Alves MG, Kodama MH, da Silva EZM, Gomes
BBM, da Silva RAA, Vieira GV, Alves VM, da Fonseca CK, Santana AC,
Cecílio NT, et al: Relative expression of KLK5 to LEKTI is
associated with aggressiveness of oral squamous cell carcinoma.
Transl Oncol. 14:1009702021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ao J, Chiba T, Kanzaki H, Kanayama K,
Shibata S, Kurosugi A, Iwanaga T, Kan M, Sakuma T, Qiang N, et al:
Serum angiopoietin 2 acts as a diagnostic and prognostic biomarker
in hepatocellular carcinoma. J Cancer. 12:2694–2701. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Song Y, Bai G, Li X, Zhou L, Si Y, Liu X,
Deng Y and Shi Y: Bioinformatics analysis of human kallikrein 5
(KLK5) expression in metaplastic triple-negative breast cancer.
Cancer Innov. 2:376–390. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kraljević M, Marijanović I, Barbarić M,
Sokolović E, Bukva M, Cerić T and Buhovac T: Prognostic and
predictive significance of VEGF, CD31, and Ang-1 in patients with
metastatic clear cell renal cell carcinoma treated with first-line
sunitinib. Biomol Biomed. 23:161–169. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Papachristopoulou G, Malachias A, Devetzi
M, Kamouza E, Scorilas A, Xynopoulos D and Talieri M: Uncovering
the clinical impact of kallikrein-related peptidase 5 (KLK5) mRNA
expression in the colorectal adenoma-carcinoma sequence. Clin Chem
Lab Med. 57:1251–1260. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Antoniotti C, Marmorino F, Boccaccino A,
Martini S, Antista M, Rossini D, Zuco V, Prisciandaro M, Conca V,
Zucchelli G, et al: Early modulation of Angiopoietin-2 plasma
levels predicts benefit from regorafenib in patients with
metastatic colorectal cancer. Eur J Cancer. 165:116–124. 2022.
View Article : Google Scholar : PubMed/NCBI
|
